智通财经APP获悉，周二，葛兰素史克(GSK.US)涨逾4%，报42.94美元。消息面上，9月29日，葛兰素 史克公司宣布卢克·米尔斯(Luke Miels)已获任命为首席执行官候选人，并将于2026年1月1日正式担任首 席执行官一职，接替现任首席执行官艾玛·沃尔姆斯利(Emma Walmsley)。米尔斯于 2017 年加入葛兰素 史克公司，目前担任首席商业官，他在构建葛兰素史克的专科药物产品组合(尤其是肿瘤学和呼吸系统 领域)方面发挥了关键作用。在加入葛兰素史克之前，米尔斯曾在阿斯利康、罗氏和赛诺菲等公司担任 过多个高级职务。 （原标题：美股异动 | 葛兰素史克(GSK.US)涨逾4% 高盛：换帅或推动投资者重新估值） 高盛认为，新任首席执行官的首要沟通内容将是向市场保证葛兰素史克实现其长期目标的策略，尤其是 其到 2031 年实现超过 400 亿英镑销售额的销售指引，这也是新闻稿中所重申的内容。此外，高盛预计 投资者将会关注新首席执行官如何能够提升公司创新能力的相关细节。高盛认为，这对于推动该股票实 现有意义的重新估值至关重要，因为该股票一直处于同行业股票的较低水平。 ...

Core Viewpoint - GlaxoSmithKline (GSK) shares rose over 4% to $42.94 following the announcement of Luke Miels as the CEO candidate, set to officially take over on January 1, 2026, from current CEO Emma Walmsley [1] Group 1: Leadership Transition - Luke Miels has been appointed as the CEO candidate and will succeed Emma Walmsley in 2026 [1] - Miels joined GSK in 2017 and currently serves as Chief Commercial Officer, playing a key role in developing GSK's specialty pharmaceuticals portfolio, particularly in oncology and respiratory fields [1] - Prior to GSK, Miels held senior positions at AstraZeneca, Roche, and Sanofi [1] Group 2: Market Expectations - Goldman Sachs believes the new CEO's primary communication will focus on assuring the market of GSK's strategy to achieve its long-term goals, particularly the sales guidance of over £40 billion by 2031, which was reiterated in the press release [1] - Investors are expected to pay close attention to how the new CEO can enhance the company's innovation capabilities, which is deemed crucial for driving a meaningful revaluation of the stock [1] - GSK's stock has been trading at lower levels compared to its industry peers, making the focus on innovation particularly significant [1]

高盛认为，新任首席执行官的首要沟通内容将是向市场保证葛兰素史克实现其长期目标的策略，尤其是 其到 2031 年实现超过 400 亿英镑销售额的销售指引，这也是新闻稿中所重申的内容。此外，高盛预计 投资者将会关注新首席执行官如何能够提升公司创新能力的相关细节。高盛认为，这对于推动该股票实 现有意义的重新估值至关重要，因为该股票一直处于同行业股票的较低水平。 智通财经APP获悉，在葛兰素史克(GSK.US)宣布更换首席执行官之后，高盛发布研报，重申对葛兰素 史克"中性"评级，目标价41美元。 9月29日，葛兰素史克公司宣布卢克·米尔斯(Luke Miels)已获任命为首席执行官候选人，并将于 2026 年 1 月 1 日正式担任首席执行官一职，接替现任首席执行官艾玛·沃尔姆斯利(Emma Walmsley)。米尔斯于 2017 年加入葛兰素史克公司，目前担任首席商业官，他在构建葛兰素史克的专科药物产品组合(尤其是 肿瘤学和呼吸系统领域)方面发挥了关键作用。在加入葛兰素史克之前，米尔斯曾在阿斯利康、罗氏和 赛诺菲等公司担任过多个高级职务。 据葛兰素史克公司称："我们注意到内部和外部候选人均曾被考虑担任这一职务。并且 ...

Group 1: Leadership Transition - Luke Miels has been appointed as the new CEO of GSK, set to take over at the start of next year, succeeding Emma Walmsley [1][2] - Miels has been with GSK since 2017 and previously oversaw the global medicines and vaccines business [2][3] - Walmsley highlighted Miels as a key partner in defining GSK's strategy and improving operating performance during her tenure [3] Group 2: Company Performance and Strategy - GSK's main challenges will include delivering blockbuster drugs and lifting the share price, which has lagged behind AstraZeneca's during Walmsley's leadership [2][4] - Under Walmsley's leadership, GSK invested heavily in vaccines, expanded its HIV business, and re-entered the oncology market, while also spinning off its consumer-health unit, Haleon Plc [3][4] - Despite these changes, GSK's shares have fallen about 10% during Walmsley's tenure, contrasting with AstraZeneca's market value, which has more than doubled [4] Group 3: Future Outlook - Analysts believe Miels is well-positioned to achieve GSK's 2031 sales target of over £40 billion ($53.7 billion) due to the groundwork laid by Walmsley [5] - Miels is expected to focus on executing the existing strategy rather than making drastic changes [5] - Some analysts express caution regarding GSK's ability to deliver new drugs before the patent expiry of its HIV medicine dolutegravir at the end of the decade [6]

Leadership Change - GSK's CEO Emma Walmsley will step down [1] - Commercial chief Luke Miels will succeed Emma Walmsley as CEO [1] Company Strategy - The drugmaker is working to replenish its product lineup [1]

Market Overview - U.S. stocks are rebounding, with the S&P 500 up 0.4%, Dow Jones Industrial Average up 0.1%, and Nasdaq composite up 0.6%, all near their all-time highs set a week ago [1] - Wall Street is experiencing gains despite concerns over a potential U.S. government shutdown [2][3] Economic Indicators - A key economic report, the September jobs report, is scheduled for release on Friday, which is crucial for understanding the labor market and economic conditions [4] - Inflation in the U.S. increased to 2.7% in August from 2.6% in July, raising hopes for continued interest rate cuts by the Federal Reserve [5] Company News - Electronic Arts shares rose 5.7% after the company confirmed it would go private in a $55 billion buyout, potentially the largest buyout by private-equity firms [1][7] - GSK's shares increased by 2.8% following the announcement of CEO Emma Walmsley's upcoming departure, with Luke Miels set to replace her [7] International Markets - European markets showed modest gains, with the CAC 40 up 0.2% and FTSE up 0.4%, while the German DAX remained unchanged [8] - Asian markets had mixed results, with Japan's Nikkei 225 down 0.7%, while Chinese markets advanced, with the Hang Seng and Shanghai Composite both up 0.9% [8] Commodity Prices - U.S. benchmark crude oil prices fell nearly 2% to $64.43 per barrel, while Brent crude declined to $67.97 per barrel amid concerns over potential oversupply [9] - Gold prices rose 1.2% to a record $3,854.60 per ounce [10]

Leadership Change - GSK's CEO Emma Walmsley will step down at the end of the year, to be succeeded by commercial chief Luke Miels [1][2] - Miels, who joined GSK from AstraZeneca in 2017, has been instrumental in developing the company's specialty medicines portfolio, particularly in oncology and respiratory areas [3] Strategic Focus - The leadership transition occurs as GSK aims to launch more drugs from its late-stage pipeline to counter the impending loss of patent protection for its leading HIV drug, dolutegravir [2][6] - Walmsley emphasized that 2026 is a crucial year for GSK to establish its direction for the next decade, marking the timing for new leadership as appropriate [2] Company Performance - Under Walmsley's leadership, GSK increased research spending and made significant investments in cancer drugs, including several acquisitions [4] - GSK's stock declined approximately 11% during Walmsley's tenure, although it saw a slight increase of about 1% in recent trading [5] Financial Targets - GSK aims to achieve sales exceeding £40 billion (approximately $53.6 billion) by 2031, up from £31.4 billion last year, although some analysts express skepticism about reaching this target [5]

Group 1 - GSK plc appointed Luke Miels as CEO Designate, effective January 1, 2026, succeeding Dame Emma Walmsley [1][3] - Miels has been with GSK since 2017 as Chief Commercial Officer, focusing on medicines and vaccines, particularly in oncology and respiratory [1][2] - GSK aims for total sales exceeding £40 billion ($53.76 billion) by 2031, marking 2026 as a pivotal year for growth [2][3] Group 2 - Walmsley will step down on December 31, 2025, but will assist the new CEO until September 30, 2026, particularly regarding geopolitical impacts and new technologies [3][4] - Under Walmsley's leadership since 2017, GSK has spun off Haleon plc and shifted focus to oncology and infectious diseases to counteract patent losses and revenue declines by 2030 [5] - GSK's stock rose by 2.36% to $40.80 during premarket trading [5]

All three are near their all-time highs set a week ago. Electronic Arts climbed after the video-game maker confirmed rumors it would be taken private in what could become the largest-ever buyout funded by private-equity firms. A key economic report will arrive Friday when the government releases its monthly jobs survey.Wall Street pushed higher early Monday despite growing anxiety over a possible U.S. government shutdown later this week.Futures for the S&P 500 rose 0.5% before the bell, while futures for ...

GSK (GSK) stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year. She will be succeeded by Luke Miels, the current chief commercial officer. Prior to joining GSK in 2017, Miels has worked across the globe at AstraZeneca (AZN), Roche (RHHBY) and Sanofi (SNY). Walmsley has led GSK for nine years and says it's time to hand the reins over to someone new. "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe t ...